Morgan K Moroi1, Emile A Bacha1, David M Kalfa1. 1. Section of Congenital and Pediatric Cardiothoracic Surgery, Division of Cardiac, Thoracic and Vascular Surgery, Department of Surgery, Morgan Stanley Children's Hospital, New York-Presbyterian Hospital/Columbia University Medical Center, New York, NY, USA.
Abstract
BACKGROUND: The Ross procedure involves autograft transplantation of the native pulmonary valve into the aortic position and reconstruction of the right ventricular outflow tract (RVOT) with a homograft. The operation offers the advantages of a native valve with excellent hemodynamic performance, the avoidance of anticoagulation, and growth potential. Conversely, the operation is technically demanding and imposes the risk of turning single-valve disease into double-valve disease. This systematic review reports outcomes of pediatric patients undergoing the Ross procedure. METHODS: An electronic search identified studies reporting outcomes on pediatric patients (mean age <18 years, max age <21 years) undergoing the Ross procedure. Long-term outcomes, including early mortality, late mortality, sudden unexpected unexplained death, reoperation due to failure of the pulmonary autograft or RVOT reconstruction, thromboembolic events, bleeding events, and endocarditis-related complications, were evaluated. RESULTS: Upon review of 2,035 publications, 30 studies and 3,156 pediatric patients were included. Patients had a median age of 9.5 years and median follow-up period of 5.7 years. Early mortality rates varied from 0.0 to 17.0% and were increased in the neonatal population. Late mortality rates were much lower (0.04-1.83%/year). Reoperation due to pulmonary autograft failure occurred at rates of 0.37-2.81%/year and reoperation due to RVOT reconstruction failure was required at rates of 0.34-4.76%/year. Thromboembolic, bleeding, and endocarditis events were reported to occur at rates of 0.00-0.58, 0.00-0.39, and 0.00-1.68%/year, respectively. CONCLUSIONS: The Ross operation offers a durable aortic valve replacement (AVR) option in the pediatric population that offers favorable survival, excellent hemodynamics, growth potential, decreased risk of complications, and avoidance of anticoagulation. Larger multi-institutional registries focusing on pediatric patients are necessary to provide more robust evidence to further support use of the Ross procedure in this population. 2021 Annals of Cardiothoracic Surgery. All rights reserved.
BACKGROUND: The Ross procedure involves autograft transplantation of the native pulmonary valve into the aortic position and reconstruction of the right ventricular outflow tract (RVOT) with a homograft. The operation offers the advantages of a native valve with excellent hemodynamic performance, the avoidance of anticoagulation, and growth potential. Conversely, the operation is technically demanding and imposes the risk of turning single-valve disease into double-valve disease. This systematic review reports outcomes of pediatric patients undergoing the Ross procedure. METHODS: An electronic search identified studies reporting outcomes on pediatric patients (mean age <18 years, max age <21 years) undergoing the Ross procedure. Long-term outcomes, including early mortality, late mortality, sudden unexpected unexplained death, reoperation due to failure of the pulmonary autograft or RVOT reconstruction, thromboembolic events, bleeding events, and endocarditis-related complications, were evaluated. RESULTS: Upon review of 2,035 publications, 30 studies and 3,156 pediatric patients were included. Patients had a median age of 9.5 years and median follow-up period of 5.7 years. Early mortality rates varied from 0.0 to 17.0% and were increased in the neonatal population. Late mortality rates were much lower (0.04-1.83%/year). Reoperation due to pulmonary autograft failure occurred at rates of 0.37-2.81%/year and reoperation due to RVOT reconstruction failure was required at rates of 0.34-4.76%/year. Thromboembolic, bleeding, and endocarditis events were reported to occur at rates of 0.00-0.58, 0.00-0.39, and 0.00-1.68%/year, respectively. CONCLUSIONS: The Ross operation offers a durable aortic valve replacement (AVR) option in the pediatric population that offers favorable survival, excellent hemodynamics, growth potential, decreased risk of complications, and avoidance of anticoagulation. Larger multi-institutional registries focusing on pediatric patients are necessary to provide more robust evidence to further support use of the Ross procedure in this population. 2021 Annals of Cardiothoracic Surgery. All rights reserved.
Authors: Wolfgang Konertz; Pascal M Dohmen; Jianshi Liu; Sven Beholz; Simon Dushe; Steffen Posner; Alexander Lembcke; Wilhelm Erdbrügger Journal: J Heart Valve Dis Date: 2005-01
Authors: Joseph B Clark; Linda B Pauliks; Ashley Rogerson; Allen R Kunselman; John L Myers Journal: Ann Thorac Surg Date: 2011-05-06 Impact factor: 4.330
Authors: Robert W Elder; Jan M Quaegebeur; Emile A Bacha; Jonathan M Chen; Francois Bourlon; Ismee A Williams Journal: J Thorac Cardiovasc Surg Date: 2012-10-11 Impact factor: 5.209
Authors: Giovanni Battista Luciani; Gianluca Lucchese; Adriano Carotti; Gianluca Brancaccio; Piero Abbruzzese; Giuseppe Caianiello; Lorenzo Galletti; Gaetano Domenico Gargiulo; Stefano Maria Marianeschi; Alessandro Mazzucco; Giuseppe Faggian; Bruno Murzi; Carlo Pace Napoleone; Marco Pozzi; Lucio Zannini; Alessandro Frigiola Journal: Heart Date: 2014-07-23 Impact factor: 5.994
Authors: Sara K Pasquali; Meryl S Cohen; David Shera; Gil Wernovsky; Thomas L Spray; Bradley S Marino Journal: J Am Coll Cardiol Date: 2007-04-16 Impact factor: 24.094
Authors: John W Brown; Parth M Patel; Jiuann-Huey Ivy Lin; Asma S Habib; Mark D Rodefeld; Mark W Turrentine Journal: Ann Thorac Surg Date: 2016-04-01 Impact factor: 4.330
Authors: Jürgen Hörer; Ulrich Stierle; Ad J J C Bogers; Joachim G Rein; Roland Hetzer; Hans H Sievers; Rüdiger Lange Journal: Eur J Cardiothorac Surg Date: 2010-01-19 Impact factor: 4.191